The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System
Open accessAbstract
Purpose To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain. Methods and Materials Fourteen patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system (CNS) radiation necrosis. All patients were required to have radiographic or biopsy proof of CNS radiation necrosis and progressive neurological symptoms or signs. Eligible patients received irradiation for head and neck carcinomas, meningioma, or low- to mid-grade gliomas. Patients were randomized to receive IV saline or bevacizumab at 3-week intervals. MRI 3-weeks after the second treatment and clinical signs and symptoms defined response or progression. Results The volumes of necrosis estimated on T2FLAIR and T1-weighted gadolinium-enhanced MRI demonstrated that, while no patient receiving placebo responded (0/7), all bevacizumab-treated patients did (5/5 randomized and 7/7 cross-over) with decreases in T2FLAIR and T1-weighted gadolinium-enhanced volumes and decrease Ktrans. All bevacizumab-treated patients – and none of the placebo-treated patients - showed improvement in neurological symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all 4 study doses, only 2 patients had experienced a recurrence of MRI changes consistent with progressive radiation necrosis, and this was the only patient to receive only 2 treatments with bevacizumab. Conclusions This class I evidence of bevacizumab efficacy in the treatment of CNS radiation necrosis justifies consideration of this treatment option for people who suffer radiation necrosis secondary to the treatment of head and neck and brain cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging
Tofts, P. S. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070113 · Cited by 1,478
Multilingual Aphasia Examination
Patterson, J. P. (2018) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-3-319-57111-9_900 · Cited by 1,096
Cancer: Principles and Practice of Oncology.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-1-142_4 · Cited by 1,068
Vascular permeability factor (VPF, VEGF) in tumor biology
Senger, D. R., Van De Water, L., Brown, L. F., Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M., & Dvorak, H. F. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665960 · Cited by 840
Crossen, J. R., Garwood, D., Glatstein, E., & Neuwelt, E. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.627 · Cited by 721
Kumar, A. J., Leeds, N. E., Fuller, G. N., Van Tassel, P., Maor, M. H., Sawaya, R. E., & Levin, V. A. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv36377 · Cited by 669
Self-citationSenger, D. R., Perruzzi, C. A., Feder, J., & Dvorak, H. F. (1986) · PubMed · Cited by 646
Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. J., Van de Water, L., & Senger, D. R. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1275 · Cited by 483
Effect of bevacizumab on radiation necrosis of the brain
Gonzalez, J., Kumar, A. J., Conrad, C. A., & Levin, V. A. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.010 · Cited by 415
Self-citationCancer: Principles and Practice of Oncology
Levi, J. A. (1987) · Pathology · doi:10.1016/s0031-3025(16)39749-5 · Cited by 404
Treatment of radiation‐induced nervous system injury with heparin and warfarin
Glantz, M. J., Burger, P. C., Friedman, A. H., Radtke, R. A., Massey, E. W., & Schold, S. C. (1994) · Neurology · doi:10.1212/wnl.44.11.2020 · Cited by 325
Radiation Injury to the Nervous System
Gutin, P. H., Leibel, S. A., Sheline, G. E., & Ironside, J. W. (1992) · Histopathology · doi:10.1111/j.1365-2559.1992.tb01025.x · Cited by 250
Radiation injury of the nervous system
Andriola, M. R. (1992) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(92)90081-r · Cited by 243
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Torcuator, R., Zuniga, R., Mohan, Y. S., Rock, J., Doyle, T., Anderson, J., Gutierrez, J., Ryu, S., Jain, R., Rosenblum, M., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9801-z · Cited by 188
Sackett, D. L., Haynes, B., Marshall, T., & Morgan, W. K. C. (1995) · Wiley eBooks · doi:10.1002/0470011815.b2a08019 · Cited by 153
Hypoxia in radiation-induced blood-spinal cord barrier breakdown.
Li, Y. Q., Ballinger, J. R., Nordal, R., Su, Z.-F., & Wong, C. S. (2001) · PubMed · Cited by 130
Cheung, M., Chan, A. S.-Y., Law, S. C. K., Chan, J., & Tse, V. K. C. (2003) · Cancer · doi:10.1002/cncr.11295 · Cited by 91
Evaluation of Lung MDCT Nodule Annotation Across Radiologists and Methods
Meyer, C. R., Johnson, T. D., McLennan, G., Aberle, D. R., Kazerooni, E. A., MacMahon, H., Mullan, B. F., Yankelevitz, D. F., van Beek, E. J. R., Armato, S. G., et al. (2006) · Academic Radiology · doi:10.1016/j.acra.2006.07.012 · Cited by 83
Memory in Neurodegenerative Disease: Biological, Cognitive, and Clinical Perspectives
(1998) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544378 · Cited by 47
Bradley, F., & FIELD, J. B. (1995) · PubMed · Cited by 34
Memory in Neurodegenerative Disease: Biological, Cognitive, and Clinical Perspectives
(2000) · Archives of Neurology · doi:10.1001/archneur.57.2.279 · Cited by 25
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationRecurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Metadata
- Authors
- Levin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S., Loghin, M., Gilbert, M. R., & Jackson, E. F.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 79
- Issue
- 5
- Pages
- 1487-1495
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2136963436
- Cited by
- 729
- References
- 24
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.